KEW Group and Denka Collaborate on a Study to Identify the Benefits of CancerPlex® NGS Testing In Japanese Cancer Patients

Cambridge, MA USA and Tokyo Japan, Oct. 20, 2015 – KEW Group Inc. (KEW), a privately held oncology services company located in Cambridge, MA, and Denka Co., Ltd., a commercial and manufacturing company of a wide range of chemical products, located in Tokyo, Japan announced a collaboration today. The aim of the collaboration is to study and evaluate the benefits of KEW’s CancerPlex® Testing in Japanese cancer patients. The study is affiliated with Niigata University.

KEW’s CancerPlex assay utilizes next-generation sequencing, or NGS, to analyze more than 400 known cancer genes involved in cancer initiation and progression. The resulting information from this tumor mutation analysis can be used by physicians to supplement other patient-specific information and assist in the determination of treatment options.

"KEW Group is pleased to collaborate with Denka on this joint program utilizing the CancerPlex genomic platform on a Japanese cohort of patients," stated Tuan Ha-Ngoc KEW's Executive Chairman. "The collaboration with leading Japanese researchers has been very productive. Bringing this exciting genomic capability to cancer patients in Japan is part of KEW’s vision of enabling oncologists anywhere to practice the best standard of care of precision medicine everywhere in the world."
“We are excited to participate in this joint activity with KEW,” said Shinsuke Yoshitaka, Denka president & CEO. “A genetic approach to patient centered medicine is one of the more promising solutions to delivering better quality of life (QOL). Denka has contributed to the quality of life and sustainability of society for 100 years by innovations in chemistry and biochemistry. I believe this synergetic study of clinically actionable results will provide highly beneficial outcomes to patients and families in Japan, other Asian countries as well as around the world.”

About CancerPlex®
CancerPlex® Solid Tumor NGS and Bioinformatics Analysis is a comprehensive evaluation of known actionable cancer genes linked to approved therapies and ongoing clinical trials. By simultaneously sequencing over 400 cancer related genes, generating a sample acceptance rate greater than 99%, and completing the shortest turn-around time of 7-10 business days from sample receipt, KEW delivers more actionable results to guide treatment selection than any other provider. KEW enables more accurate prescription of targeted therapies, resulting in improved outcomes, better care and reduced health care costs.

About the KEW Group
KEW is revolutionizing cancer care by empowering oncologists to access and apply genomic insights in order to design optimal, individualized treatment approaches for patients. KEW gives oncologists practical, action-oriented solutions by coupling comprehensive patient-specific genomic data together with evidence-based information about approved and emerging therapies to help guide treatment decisions and advance optimal patient care. KEW’s first product, CancerPlex® Solid Tumor NGS and Bioinformatics Analysis, is one of the most comprehensive genetic/genomic tests available for the accurate, thorough, and timely molecular diagnosis of solid tumors. KEW Group Inc. is a privately held oncology services company located in Cambridge, MA, USA.
About Denka Group
Denka Co., Ltd. (Denka) was founded in 1915 and is headquartered in Tokyo, Japan. Denka manufactures and distributes a wide range of chemical products, encompassing organic and inorganic materials, polymer processing, electronic materials and pharmaceuticals. Denka Seiken Co., Ltd., a core Denka Group subsidiary is a leader in the fields of vaccines and diagnostic reagents. Denka is developing next generation diagnostics which enable patient centered medicines.

Contact:
KEW Group Inc.
Mark D. Myslinski
mmyslinski@kewgroup.com
www.kewgroup.com
www.cancerplex.com

Denka Co., Ltd
Noriyuki Shimizu
csr-koho@denka.co.jp
http://www.denka.co.jp/eng/